Crinetics (CRNX) Officer Executes Option Exercise and 10b5-1 Sale on Aug 22
Rhea-AI Filing Summary
Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, executed transactions on 08/22/2025 reported on this Form 4. The filing discloses an exercise of a stock option to acquire 30,000 shares at an exercise price of $16.89 per share and an open-market sale of 30,000 shares executed under a Rule 10b5-1 trading plan adopted May 21, 2025.
The sale had a volume-weighted average price of $30.43 per share and a transaction-day price range of $30.00 to $30.98. Following the transactions the reporting person shows 66,270 shares beneficially owned directly and reports 30,000 underlying shares from the option; the Form lists 89,042 derivative securities beneficially owned following the reported transactions. The sale was effected automatically pursuant to the 10b5-1 plan.
Positive
- Transaction executed under a Rule 10b5-1 plan, indicating the sale was pre-planned and automated
- Option exercise converted 30,000 options into shares, reflecting realized value for the reporting person
Negative
- Direct beneficial ownership decreased to 66,270 shares following the reported sale
- Sale involved 30,000 shares, which may be perceived by some investors as insider liquidation
Insights
TL;DR Insider exercised options and sold shares under a 10b5-1 plan, generating realized proceeds at a VWAP of $30.43.
The reporting shows a routine executive exercise-and-sale on 08/22/2025 by the Chief Medical and Development Officer. The option exercise price of $16.89 versus the sale VWAP of $30.43 indicates a material per-share gain for the reporting person, but the transactions were executed pursuant to a pre-existing 10b5-1 plan which limits interpretation as an information-driven trade. The filing states the sale was automatic and provides the sales price range; no additional company-specific operational or financial disclosures are included.
TL;DR This Form 4 documents a compliant, pre-planned insider sale following option exercise; it is a routine governance disclosure.
The Form 4 identifies adherence to Rule 10b5-1 via a plan adopted May 21, 2025, which supports the affirmative defense for automatic sales. Vesting terms for the option are disclosed in the exhibit text, showing time-based vesting with partial vesting beginning 09/30/2023 and monthly installments thereafter. From a governance perspective, the filing provides required transparency but does not signal a change in company strategy or governance structure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
| Exercise | Common Stock | 30,000 | $16.89 | $507K |
| Sale | Common Stock | 30,000 | $30.43 | $913K |
Footnotes (1)
- The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $30.43 per share. The range of sales prices on the transaction date was $30.00 to $30.98 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
